SCHEMBL1015168

SCHEMBL1015168

Cc1cc(C)cc(-c2ccc(C)c(NC(=O)CSCC(=O)Nc3ccc(Cl)cc3C(=O)O)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 3/20 0.49
GAA P10253 3/20 0.49
MAPT P10636 1/20 0.49
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 2/20 0.47
TP53 P04637 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.44
SERPINE1 P05121 3/20 0.44
LMNA P02545 1/20 0.44
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016193 0.90 ALDH1A1 (0.47) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL1015691 0.87 ALDH1A1 (0.52) ALDH1A1GAAMAPTHSD17B10KDM4E
SCHEMBL1013304 0.87 SERPINE1 (0.59) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL1013557 0.78 ALDH1A1 (0.54) ALDH1A1GAAMAPTKDM4ETP53
SCHEMBL1016855 0.77 SERPINE1 (0.50) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL1015571 0.76 SERPINE1 (0.59) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL417712 0.76 TP53 (0.64) ALDH1A1MAPTHSD17B10KDM4ETP53
SCHEMBL1015626 0.76 RXFP1 (0.53) ALDH1A1GAAMAPTHSD17B10KDM4E
SCHEMBL1013513 0.76 SERPINE1 (0.68) ALDH1A1GAAMAPTHSD17B10KDM4E
SCHEMBL1015322 0.75 ALDH1A1 (0.54) MEN1KMT2AALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 MEN1 892/4885KMT2A 3970/4885ALDH1A1 888/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 MEN1 1229/4885KMT2A 3323/4885ALDH1A1 273/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 MEN1 1187/4885KMT2A 3437/4885ALDH1A1 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.